Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

AUTOR(ES)

Sabatino, Marianna

FONTE

American Society of Clinical Oncology

Documentos Relacionados

• Cardiomyopathy associated with high-dose interleukin-2 therapy.
• Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma.
• High-dose narrative
• Peripheral neuropathy during longterm high-dose amiodarone therapy.
• Effect of saturable clearance during high-dose mezlocillin therapy.